Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 8, 2009, Pages 2847-2852

  Laing, Rachel E ^a   Walter, Martin A ^a   Campbell, Dean O ^a   Herschman, Harvey R ^a   Satyamurthy, Nagichettiar ^a   Phelps, Michael E ^a   Czernin, Johannes ^a   Witte, Owen N ^a   Radu, Caius G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

18F FAC; Individualized chemotherapy; Molecular imaging deoxycytidine kinase

Indexed keywords

1 (2' DEOXY 2' FLUOROARABINOFURANOSYL)CYTOSINE F 18; DEOXYCYTIDINE KINASE; GEMCITABINE; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MALE; MOLECULAR PROBE; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSINE; DEOXYCYTIDINE; HUMANS; LEUKEMIA; MICE; POSITRON-EMISSION TOMOGRAPHY;

ARA; MURINAE; MUS;

EID: 62549110462     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812890106     Document Type: Article

References (47)

1. Contag CH (2007) In vivo pathology: Seeing with molecular specificity and cellular resolution in the living body. Annu Rev Pathol 2:277-305.
2. Weber WA, Czernin J, Phelps ME, Herschman HR (2008) Technology insight: Novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract 5:44-54.
3. Evilevitch V, et al. (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715-720.
4. Gayed I, et al. (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17-21.
5. Goerres GW, et al. (2005) The value of PET, CT, and in-line PET/CT in patients with gastrointestinal stromal tumours: Long-term outcome of treatment with imatinib mesylate. Eur J Nud Med Mol imaging 32:153-162.
6. Dose Schwarz J, et al. (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nud Med 46:1144-1150.
7. Weber WA, et al. (2003) Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21:2651-2657.
8. Lordick F, et al. (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial Lancet Oncol 8:797-805.
9. Peterson LM, et al. (2008) Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49:367-374.
10. Linden HM, et al. (2006) Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24:2793-2799.
11. Cheng Z, et al. (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules J Nucl Med 49:804-813.
12. Faderl 5, et al. (2005) The role of clofarabine in hematologic and solid malignancies: Development of a next-generation nucleoside analog. Cancer 103:1985-1995.
13. Jordheim LP, Dumontet C (2007) Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 1776:138-159.
14. Jordheim LP, et al. (2004) Characterization of a gemcitabine-resistant murine leukemic cell line: Reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res 10:5614-5621.
15. Kroep JR, et al. (2002) Pretreatment deoxycytidine kinase levels predict in vivo gem-citabine sensitivity. Mo! Cancer Ther 1:371-376.
16. Galmarini CM, et al. (2004) Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 4:8.
17. Shi JY, etal. (2004) Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14:759-768.
18. mba JK, et al. (2007) Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. J Pharmacol Exp Ther 323:935-945.
19. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Update 5:19-33.
20. Sebastiani V, et al. (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12:2492-2497.
21. Ueno H, Kiyosawa K, Kaniwa N (2007) Pharmacogenomics of gemcitabine: Can genetic studies lead to tailor-made therapy? Br J Cancer 97:145-151.
22. Sigmond J, Kroep JR, Loves W, Codacci-Pisanelli G, Peters GJ (2004) Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity. Cancer Lett 213:173-179.
23. Hubeek I, et al. (2005) Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours. J Clin Pathol 58:695-699.
24. Radu CG, et al. (2008) Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new 18F-labeled 2'-deoxycytidine analog. Nat Med 14:783-788.
25. Usova EV, Eriksson S (1997) The effects of high salt concentrations on the regulation of the substrate specificity of human recombinant deoxycytidine kinase. Eur J Biochem-istry/FEBS 248:762-766.
26. Owens JK, Shewach DS, Ullman B, Mitchell BS (1992) Resistance to 1-jβ-D-arabino-furanosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 52:2389-2393.
27. Colucci G,et a/. (2002) Gemcitabine alone or with cisplatinforthe treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'ltalia Meridionale. Cancer 94:902-910.
28. Heinemann V, et al. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952.
29. Pauwels B, et al. (2006) The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer 6:142.
30. Heidel JD, et a/. (2007) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13:2207-2215.
31. Heidel JD, et al. (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104:5715-5721.
32. Duxbury MS, I to H,Zinner MJ, Ashley SW, Whang EE (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23:1539-1548.
33. Huang SC, et al. (2005) An internet-based "kinetic imaging system" (KIS) for microPET Mo! Imaging Biol 7:330-341.
34. Adjei AA (2006) Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 17 (Suppl 5):v29-v32.
35. Dittmann H, et al. (2002) Early changes in [18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging 29:1462-1469.
36. Bengala C, et al. (2005) Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 93:35-40.
37. Bergman AM, et al. (2005) In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65:9510-9516.
38. Davidson JD, et al. (2004) An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64:3761-3766.
39. Han Z, et al. (2008) Noninvasive assessment of cancer response to therapy. Nat Med 14:343-349.
40. Rosen MA, Schnall MD (2007) Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 13:770s-776s.
41. Segal E, et al. (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675-680.
42. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H (2002) Patient dosimetry for 131 l-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol imaging 29:1581-1587.
43. Hawley RG, Lieu FH, Fong AZ, HawleyTS (1994) Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1:136-138.
44. Smal C, et al. (2006) Identification of in vivo phosphorylation sites on human deoxycytidine kinase: Role of Ser-74 in the control of enzyme activity. J Biol Chem 281:4887-4893.
45. Petty RD, Sutherland LA, Hunter EM, CreelA(1995) Comparison of MTTand ATP-based assays for the measurement of viable cell number. J Biolum Chemilum 10:29-34.
46. Koresawa M, Okabe T (2004) High-throughput screening with quantitation of ATP consumption: A universal nonradioisotope, homogeneous assay for protein kinase Assay Drug Dev Technol 2:153-160.
47. Smal C, et al. (2004) New evidences for a regulation of deoxycytidine kinase activity by reversible phosphorylation. Nucleosides Nucleotides Nucleic Acids 23:1363-1365.